2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831
Norristown, Pennsylvania 21 July 2014
PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that it received notice from the United States Patent and Trademark Office (USPTO) that new patent claims will be allowed for its Advanced PluroGel® Biomaterial. PluroGen expects a new patent to issue.
The claims noted by the USPTO that will be allowed cover the special ability of the Company’s advanced PluroGel® Biomaterial to have a positive effect in preventing or dispersing biofilms in wounds. Biofilm establishment in a wound is thought to prevent wound healing. PluroGel’s ability prevent or disperse biofilms is a significant performance feature differentiating PluroGel® products and giving them important competitive advantage.
“Receiving a new patent that directly covers our advanced PluroGel® Biomaterial products will be an important new strategic asset for the Company adding protection and value for Plurogen and its investors” noted Neal Koller, President and CEO of PluroGen.
For Immediate Release
Contact: Neal Koller
President & CEO
+1 (610) 539‐3670